Julphar launches Turox in UAE
RAS AL KHAIMAH, February 18, 2016
Julphar Gulf Pharmaceutical Industries, a leading generic pharmaceutical manufacturer in Middle East and North Africa (Mena) region, has launched Turox in the UAE.
The once-daily non-steroidal anti-inflammatory drug (NSAD) Turox belongs to a new class of arthritis/analgesia medications called Coxibs, said a statement.
It is a highly selective inhibitor of cyclooxygenase-2 that is used for the treatment of painful acute and chronic inflammatory conditions, it said.
Dr Aly Mousa, vice president - Sales & Marketing, Julphar, said: “Today marks the kick-off of the Julphar’s collaboration with the global industry leader Merck Sharp & Dohme (MSD).
“By partnering with MSD and launching the second brand of MSD’s Etoricoxib product, Turox – the first MSD second brand of a series of five – Julphar takes a major step towards addressing patients’ needs in Mena and commits to work on improving access to healthcare.”
The Turox launch is part of the manufacturing partnership signed by MSD and Julphar in April 2014.
Under the terms of this license and supply agreement, MSD grants Julphar exclusive rights to commercialise and distribute five MSD second brands in the areas of diabetes, asthma, allergy, pain and inflammation across the UAE, Kuwait, Bahrain, Oman, Qatar and Iraq.
The venture is a result of the mutual commitment to improve patients’ accessibility to effective medication treatments and to deliver enhanced therapeutic choices to clinicians who care for them. - TradeArabia News Service
